when were glp 1 drugs approved The Landscape Of GLP-1 Receptor Agonists In Diabetes And Obesity Treatment Weight-loss drugs such as Ozempic

N Engl J Med 2001;345:851-60.ArticlePubMed 10

Efficacy of glucagon-like peptide-1 mimetics for neural regeneration

When they come back to Earth, their muscles are a little bit weaker, and many show decreased bone density

Appetite suppression typically begins around week 3 Average weight loss: 3-4% of starting weight Side effects are usually mild at lower starting doses Establishing hydration habits is critical during this phase Most users can eat normally with slightly smaller portions Proactive hydration habits established during month 1 pay dividends later

the overall 12-month discontinuation rate for GLP-1 agonists is estimated at 36.5%, with higher rates observed in patients with obesity alone compared to those with type 2 diabetes

One study from February 2025, for instance, suggests that people who take glucagon-like peptide-1 receptor agonist medication like Ozempic to treat diabetes have a lower depression risk than peers taking other types of drugs for this metabolic condition